Squamous Cell Differentiation in Metastatic Papillary Thyroid Carcinoma: Metaplastic

Handra-Luca, Adriana

doi:10.30699/ijp.13.2.276

Home Articles List Article Information

|
|
|
How to cite
RIS EndNote BibTeX APA MLA Harvard Vancouver
|
Share

Articles in Press

Current Issue

Journal Archive

Volume 14 (2019)

Volume 13 (2018)

Issue 4

Issue 3

Issue 2

Issue 1

Volume 12 (2017)

Volume 11 (2016)

Volume 10 (2015)

Volume 9 (2014)

Volume 8 (2013)

Volume 7 (2012)

Volume 6 (2011)

Volume 5 (2010)

Volume 4 (2009)

Volume 3 (2008)

Volume 2 (2007)

Volume 1 (2006)

	Squamous Cell Differentiation in Metastatic Papillary Thyroid Carcinoma: Metaplastic
Article 21, Volume 13, Issue 2, Spring 2018, Page 276-280 PDF (409.49 K)
Document Type: Case Reports
DOI: 10.30699/ijp.13.2.276
Author
Adriana Handra-Luca ¹^{, 2}
¹APHP GHU Avicenne, Bobigny, France
²Université Paris Nord Sorbonne Cite, Bobigny, France
Abstract
Squamous cell differentiation (SCD) may occur in papillary thyroid carcinoma (PTC) only at metastatic sites. We have studied cytokeratin CK5/6 and P63 along with TTF1 (thyroid transcription factor 1) and B-Raf (V-Raf murine sarcoma viral oncogene homolog B1) immunohistochemical expression in neck lymph node metastases of thyroid PTC showing SCD. The patient (21-years) presented with a neck mass. The check-up revealed bilateral thyroid nodules. Total thyroidectomy and neck lymph node dissection were performed. The diagnosis was that of bilateral PTC with lymph node metastases (pT1N1Mx). The metastases were peculiar by the presence of cystic change and of SCD. The thyroid PTC expressed P63 focally and, TTF1 and B-Raf diffusely. Cytokeratin 5/6 was expressed only in the lymph node metastases, in the metastatic cyst lining and in the SCD foci. The P63+ cells outnumbered those CK5/6+. TTF1 expression was faint in SCD. Metastatic, both classical PTC- and SCD-epithelia expressed B-Raf. The expression patterns of CK5/6, P63, TTF1 suggest a luminal/central-to-abluminal/peripheral direction for SCD development from PTC-epithelia in lymph node metastases. Whether this metaplasia type may reflect a regression to a less aggressive morphotype or a progression-switch to squamous cell carcinoma-type differentiation in a composite tumor remains matter of debate.
Highlights
Lymph node metastases thyroid papillary thyroid carcinoma may show squamous cell differentiation. The immunophenotype of this type of metaplasia is CK5/6 P63 TTF1 (thyroid transcription factor 1), thyroglobulin and, B-Raf (V-Raf murine sarcoma viral oncogene homolog B1). Squamous cell differentiation in AHL: papillary thyroid carcinoma (PTC) cervical lymph node metastasis has to be from a synchronous primary squamous cell carcinoma of a lung or other origin
Keywords
Thyroid; Lymph Nodes; Metaplasia; Carcinoma; Cell Differentiation; Keratins
Main Subjects
ENT & Ophthalmic Pathology


References
Acosta AM, Pins MR. Papillary thyroid carcinoma with extensive squamous dedifferentiation metastatic to the lung: BRAF mutational analysis as a useful tool to rule out tumor to tumor metastasis. Virchows Arch 2016;468(2):239-42. https://doi.org/10.1007/s00428-015-1875-8 PMid:26521063 Harada T, Shimaoka K, Katagiri M, Shimizu M, Hosoda Y, Ito K. Rarity of squamous cell carcinoma of the thyroid: autopsy review. World J Surg 1994;18(4):542-6. https://doi.org/10.1007/BF00353760 PMid:7725742 Katoh R, Sakamoto A, Kasai N, Yagawa K. Squamous differentiation in thyroid carcinoma. With special reference to histogenesis of squamous cell carcinoma of the thyroid. Acta Pathol Jpn. 1989;39(5):306-12. https://doi.org/10.1111/j.1440-1827.1989.tb02440.x Klinck GH, Menk KF. Squamous cells in the human thyroid. Mil Surg. 1951;109(4):406-14. https://doi.org/10.1093/milmed/109.4.406 Rosai J. Rosai and Ackerman's Surgical Pathology. 10ed. Philadelphia PA: Elsevier; 2011. Kunisue H, Mikami Y, Tanaka K, Sonoo H, Udagawa K, Yamamoto Y, et al. Metastatic papillary thyroid carcinoma of the submandibular lymph nodes with extensive squamous metaplasia: report of a case. Surg Today. 2003;33(10):751-4. https://doi.org/10.1007/s00595-003-2581-8 PMid:14513322 Bond JA, Wyllie FS, Ivan M, Dawson T, Wynford-Thomas D. A variant epithelial sub-population in normal thyroid with high proliferative capacity in vitro. Mol Cell Endocrinol. 1993;9(2):175-83. https://doi.org/10.1016/0303-7207(93)90121-Y Jensen K, Patel A, Larin A, Hoperia V, Saji M, Bauer A, et al. Human herpes simplex viruses in benign and malignant thyroid tumours. J Pathol. 2010;221(2):193-200. https://doi.org/10.1002/path.2701 PMid:20455254 Thomas D, Liakos V, Michou V, Kapranos N, Kaltsas G, Tsilivakos V, et al. Detection of herpes virus DNA in post-operative thyroid tissue specimens of patients with autoimmune thyroid disease. Exp Clin Endocrinol Diabetes. 2008;116(1):35-9. https://doi.org/10.1055/s-2007-956171 PMid:18240111 Benvenga S, Alesci S, Trimarchi F, Facchiano A. Homologies of the thyroid sodium-iodide symporter with bacterial and viral proteins. J Endocrinol Invest. 1999;22(7):535-40. https://doi.org/10.1007/BF03343605 PMid:10475151 Rausch T, Benhattar J, Sutter M, Andrejevic-Blant S. Thyroid carcinoma with papillary and squamous features: report of a case with histogenetic considerations. Pathol Res Pract. 2010;206(4):263-9. https://doi.org/10.1016/j.prp.2009.05.003 PMid:19493635 Romano RA, Ortt K, Birkaya B, Smalley K, Sinha S. An active role of the DeltaN isoform of p63 in regulating basal keratin genes K5 and K14 and directing epidermal cell fate. PLoS One. 2009;4(5):e5623. https://doi.org/10.1371/journal.pone.0005623 PMid:19461998 PMCid:PMC2680039 Cameselle-Teijeiro J, Abdulkader I, Pérez-Becerra R, Vázquez-Boquete A, Alberte-Lista L, Ruiz-Ponte C et al. BRAF mutation in solid cell nest hyperplasia associated with papillary thyroid carcinoma. A precursor lesion? Hum Pathol. 2009;40(7):1029-35. https://doi.org/10.1016/j.humpath.2008.11.015 PMid:19269016 Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22(29):4578-80. https://doi.org/10.1038/sj.onc.1206706 PMid:12881714 Nowara E, Huszno J, Slomian G, Nieckula J. Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib. Postepy Dermatol Alergol. 2016;33(1):52-6. https://doi.org/10.5114/pdia.2015.48045 PMid:26985180 PMCid:PMC4793055
Statistics Article View: 205 PDF Download: 109